Current Advances in γδ T Cell-Based Tumor Immunotherapy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
γδ T cells are a minor population (∼5%) of CD3 T cells in the peripheral blood, but abound in other anatomic sites such as the intestine or the skin. There are two major subsets of γδ T cells: those that express Vδ1 gene, paired with different Vγ elements, abound in the intestine and the skin, and recognize the MHC class I-related molecules MICA, MICB and ULBPs expressed on many stressed and tumor cells. Conversely, γδ T cells expressing the Vδ2 gene paired with the Vγ9 chain, are the predominant (50% to 90%) γδ T cell population in the peripheral blood and recognize phosphoantigens (PAgs) derived from the mevalonate pathway of mammalian cells, which is highly active upon infection or tumor transformation. Aminobisphosphonates (n-BPs), which inhibit farnesyl pyrophosphate synthase, a downstream enzyme of the mevalonate pathway, cause accumulation of upstream PAgs and therefore promote γδ T cell activation. γδ T cells have distinctive features that justify their utilization in anti-tumor immunotherapy: they do not require MHC restriction and are less dependent that αβ T cells on co-stimulatory signals, produce cytokines with known anti-tumor effects as IFN-γ and TNF-α and display cytotoxic and anti-tumor activities in vitro and in mouse models in vivo. Thus, there is interest in the potential application of γδ T cells in tumor immunotherapy and several small-sized clinical trials have been conducted of γδ T cell-based immunotherapy in different types of cancer after the application of PAgs or n-BPs plus IL-2 in vivo or after adoptive transfer of ex vivo expanded γδ T cells, particularly the Vγ9Vδ2 subset. Results from clinical trials testing the efficacy of any of these two strategies have shown that γδ T cell-based therapy is safe, but long-term clinical results to date are inconsistent. In this review we will discuss the major achievements and pitfalls of the γδ T cell-based immunotherapy of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Six-of-the-best: unique contributions of γδ T cells to immunology
Vantourout, P., & Hayday, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3384 · Cited by 1,232
Silva-Santos, B., Serre, K., & Norell, H. (2015) · Nature reviews. Immunology · doi:10.1038/nri3904 · Cited by 565
Themeli, M., Kloss, C. C., Ciriello, G., Fedorov, V. D., Perna, F., Gonen, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2678 · Cited by 473
MICA Engagement by Human Vγ2Vδ2 T Cells Enhances Their Antigen-Dependent Effector Function
Das, H., Groh, V., Kuijl, C., Sugita, M., Morita, C. T., Spies, T., & Bukowski, J. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00168-6 · Cited by 409
Cited by
Xu, Y., Xiang, Z., Alnaggar, M., Kouakanou, L., Li, J., He, J., Yang, J., Hu, Y., Chen, Y., Lin, L., et al. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0515-7 · Cited by 263
Human γδ T-Cell Control of Mucosal Immunity and Inflammation
McCarthy, N. E., & Eberl, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00985 · Cited by 96
Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors
Yakkala, C., Chiang, C. L.-L., Kandalaft, L., Denys, A., & Duran, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02283 · Cited by 88
γδ T Cells in Tumor Microenvironment
Imbert, C., & Olive, D. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-49270-0_5 · Cited by 27
Metadata
- Authors
- Lo Presti, E., Pizzolato, G., Gulotta, E., Cocorullo, G., Gulotta, G., Dieli, F., & Meraviglia, S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-10-27
- Volume
- 8
- Pages
- 1401-1401
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2766131970
- Cited by
- 78
- References
- 5
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.